Browsing by Author "Acar Ö."

Now showing 1 - 8 of 8
  • No Thumbnail Available
    Item
    Level of COVID-19 fear in cancer patients
    (Springer Science and Business Media Deutschland GmbH, 2022) Erdoğan A.P.; Ekinci F.; Acar Ö.; Göksel G.
    Background: Cancer patients are in the high-risk group of getting COVID-19 infection and experiencing a severe course. Anxiety of cancer patients about how they pass this pandemic process and how changes in the health system would influence their treatment has increased together with the COVID-19 pandemic. Influence of COVID-19 on psychology of cancer patients is also a subject needed to be investigated as well as its course and prognosis. Thus, it is aimed to measure fear levels of cancer patients by a validated scale. Patients accepting to fill in the validated Fear of COVID-19 (FCV-19S) scale were included in our study. Higher scores obtained from the scale means high level of COVID-19 fear was experienced. Results: A total of 66.8% of 486 patients expressed that they are very afraid of coronavirus, and 66.3% expressed that they fear from losing their lives due to coronavirus. The level of fear in the patient group having adjuvant therapy has been found statistically to be significantly higher compared with groups having neoadjuvant and metastatic/palliative therapy (p: 0.004). Conclusions: Because the increase of level of fear may lead to vital outcomes such as weakening of immune system, disturbance of treatment compliance, and worsening of prognosis, a psychological approach to cancer patients is compulsory in order to prevent fear of COVID-19 infection. © 2022, The Author(s).
  • No Thumbnail Available
    Item
    Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
    (Churchill Livingstone, 2022) Yıldırım H.Ç.; Mutlu E.; Chalabiyev E.; Özen M.; Keskinkılıç M.; Ön S.; Çelebi A.; Dursun B.; Acar Ö.; Kahraman S.; Aykan M.B.; Kaman Ö.; Doğan A.; Erdoğan A.P.; Melisa Celayir Ö.; Günenç D.; Güven D.C.; Vedat Bayoğlu İ.; Yavuzşen T.; Hacıbekiroğlu İ.; İnanç M.; Kılıçkap S.; Yalçın Ş.; Aksoy S.
    Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore; we aimed to investigate the treatment responses of metastatic HR+, HER2-male breast cancer patients treated with CDK 4–6 inhibitors in a multicenter real-life cohort. Methods: Male patients with a diagnosis of HR+ and HER2-metastatic breast cancer, treated with any CDK 4–6 inhibitor, were included in the study. Demographic and clinical characteristics of the patients were recorded. We aimed to determine progression-free survival (PFS) time, response rates and drug related side effects. Results: A total 25 patients from 14 institutions were recruited. The mean age at diagnosis was 57 years. Median follow-up was 19.53 (95% CI: 14.04–25.02) months. The overall response rate was 60%. While the median PFS was 20.6 months in the whole cohort, it wasn't reached in those using CDK 4–6 inhibitors in first line and 10 months in the subsequent lines (p:0.009). No new adverse events were encountered. Conclusion: In our study, we found that CDK 4–6 inhibitors are effective and safe options in men with HR+ and HER2-metastatic breast cancer as in women. Our results support the use of CDK 4–6 inhibitor-based combinations in the first-line treatment of HR+ and HER2-metastatic male breast cancer. © 2022
  • No Thumbnail Available
    Item
    Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    (BioMed Central Ltd, 2023) Karacin C.; Oksuzoglu B.; Demirci A.; Keskinkılıç M.; Baytemür N.K.; Yılmaz F.; Selvi O.; Erdem D.; Avşar E.; Paksoy N.; Demir N.; Göksu S.S.; Türker S.; Bayram E.; Çelebi A.; Yılmaz H.; Kuzu Ö.F.; Kahraman S.; Gökmen İ.; Sakin A.; Alkan A.; Nayır E.; Uğraklı M.; Acar Ö.; Ertürk İ.; Demir H.; Aslan F.; Sönmez Ö.; Korkmaz T.; Celayir Ö.M.; Karadağ İ.; Kayıkçıoğlu E.; Şakalar T.; Öktem İ.N.; Eren T.; Urul E.; Mocan E.E.; Kalkan Z.; Yıldırım N.; Ergün Y.; Akagündüz B.; Karakaya S.; Kut E.; Teker F.; Demirel B.Ç.; Karaboyun K.; Almuradova E.; Ünal O.Ü.; Oyman A.; Işık D.; Okutur K.; Öztosun B.; Gülbağcı B.B.; Kalender M.E.; Şahin E.; Seyyar M.; Özdemir Ö.; Selçukbiricik F.; Kanıtez M.; Dede İ.; Gümüş M.; Gökmen E.; Yaren A.; Menekşe S.; Ebinç S.; Aksoy S.; İmamoğlu G.İ.; Altınbaş M.; Çetin B.; Uluç B.O.; Er Ö.; Karadurmuş N.; Erdoğan A.P.; Artaç M.; Tanrıverdi Ö.; Çiçin İ.; Şendur M.A.N.; Oktay E.; Bayoğlu İ.V.; Paydaş S.; Aydıner A.; Salim D.K.; Geredeli Ç.; Yavuzşen T.; Doğan M.; Hacıbekiroğlu İ.
    Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET. © 2023, The Author(s).
  • No Thumbnail Available
    Item
    Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (BMC Cancer, (2023), 23, 1, (136), 10.1186/s12885-023-10609-8)
    (BioMed Central Ltd, 2023) Karacin C.; Oksuzoglu B.; Demirci A.; Keskinkılıç M.; Baytemür N.K.; Yılmaz F.; Selvi O.; Erdem D.; Avşar E.; Paksoy N.; Demir N.; Göksu S.S.; Türker S.; Bayram E.; Çelebi A.; Yılmaz H.; Kuzu Ö.F.; Kahraman S.; Gökmen İ.; Sakin A.; Alkan A.; Nayır E.; Uğraklı M.; Acar Ö.; Ertürk İ.; Demir H.; Aslan F.; Sönmez Ö.; Korkmaz T.; Celayir Ö.M.; Karadağ İ.; Kayıkçıoğlu E.; Şakalar T.; Öktem İ.N.; Eren T.; Erul E.; Mocan E.E.; Kalkan Z.; Yıldırım N.; Ergün Y.; Akagündüz B.; Karakaya S.; Kut E.; Teker F.; Demirel B.Ç.; Karaboyun K.; Almuradova E.; Ünal O.Ü.; Oyman A.; Işık D.; Okutur K.; Öztosun B.; Gülbağcı B.B.; Kalender M.E.; Şahin E.; Seyyar M.; Özdemir Ö.; Selçukbiricik F.; Kanıtez M.; Dede İ.; Gümüş M.; Gökmen E.; Yaren A.; Menekşe S.; Ebinç S.; Aksoy S.; İmamoğlu G.İ.; Altınbaş M.; Çetin B.; Uluç B.O.; Er Ö.; Karadurmuş N.; Erdoğan A.P.; Artaç M.; Tanrıverdi Ö.; Çiçin İ.; Şendur M.A.N.; Oktay E.; Bayoğlu İ.V.; Paydaş S.; Aydıner A.; Salim D.K.; Geredeli Ç.; Yavuzşen T.; Doğan M.; Hacıbekiroğlu İ.
    Following publication of the original article [1], the authors reported an error in the author name of Enes Erul. Incorrect: Enes Urul Correct: Enes Erul, The original article [1] has been corrected. © 2023, The Author(s).
  • No Thumbnail Available
    Item
    The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
    (Springer, 2024) Yıldırım H.Ç.; Kutlu Y.; Mutlu E.; Aykan M.B.; Korkmaz M.; Yalçın S.; Şakalar T.; Celayir Ö.M.; Kayıkçıoğlu E.; Aslan F.; Hafızoğlu E.; Altıntaş Y.E.; Keskinkılıç M.; Chalabiyev E.; Çelebi A.; Dursun B.; Kapar C.; Özen M.; Acar Ö.; Dülgar Ö.; Kut E.; Biter S.; Kus F.; Almuradova E.; Erdoğan A.P.; Saray S.; Güven D.C.; Şimşek E.T.; Üskent N.; Kemal Y.; Çakar B.; Açıkgöz Ö.; Kılıçkap S.; Aksoy S.
    Introduction: Male breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 −) breast cancer in women, limited data exist on their effectiveness in male patients. We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer. Methods: This study is a multicenter, retrospective study. We included male patients with HR + and HER2-metastatic breast cancer who received palbociclib or ribociclib as first-line treatment. Our primary endpoints were progression-free survival (PFS), overall response rates (ORR), and drug-related adverse effects. Results: A total of 46 male patients from 27 institutions were enrolled. The median age at initiation of CDK 4/6 inhibitors was 63.64 ± 13.69 years, with a median follow-up of 21.33 (95% CI 14.92–27.74) months. The ORR were 84% for palbociclib and 76.2% for ribociclib. The mPFS for the entire cohort was 28.06 months (95% CI 18.70–37.42). No significant difference in PFS was observed between palbociclib and ribociclib (mPFS: 24.46 months (95% CI 11.51–37.42) vs 28.33 months (95% CI 14.77–41.88), respectively, p = 0.211). No new adverse events were reported. Discussion: This study demonstrates that palbociclib and ribociclib are effective and safe options for first-line treatment in male patients with HR + /HER2 − metastatic breast cancer. However, further prospective studies are warranted to establish their efficacy in this population. © The Author(s) under exclusive licence to Japan Society of Clinical Oncology 2024.
  • No Thumbnail Available
    Item
    The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
    (Nature Research, 2024) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aydın E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
    The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1–3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2–0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1–0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied. © The Author(s) 2024.
  • No Thumbnail Available
    Item
    The effect of cardiometabolic control and malnutrition on the prevalence and prognosis of diabetic retinopathy in type 2 diabetes; [Tip 2 diyabette kardiyometabolik kontrol ve malnütrisyonun diyabetik retinopati prevalansı ve prognozuna etkisi]
    (Pamukkale University, 2024) Özdemir M.; Dağ Y.; Uzunlulu M.; Oğuz A.; Ardagil A.; Acar Ö.; Selbest B.
    Purpose: This study aims to investigate the predictive value of cardiometabolic control, gamma glutamyl transferase (GGT) and malnutrition-related inflammation markers for predicting diabetic retinopathy (DR) prevalence and prognosis. Materials and methods: Type 2 Diabetes Mellitus patients who were consecutively admitted to Internal and Ophthalmology outpatient clinics were included in this study. Clinical, haematological and biochemical data were recorded. Cut-off values of GGT, hemoglobin, albumin, lymphocyte and platelet (HALP) score, nutritional risk index (NRI) and prognostic nutritional index (PNI) scores were determined by receiver operator characteristic curve analysis. Univariate and multivariate analyses were performed to determine the association of all variables with DR. We evaluated which of these tests were predictive and prognostic for the development of DR. Results: This study included 166 patients. Fasting blood glucose (p<0.001), creatinine (p=0.01), HbA1c (p<0.001) and microalbuminuria (p=0.01) were higher in patients with retinopathy. Mean arterial pressure (p=0.01), fasting blood glucose (p=0.03), triglyceride (p=0.008), body mass index (BMI) (p=0.02) and HbA1c (p=0.04) increased significantly as GGT level increased. Contrary to the literature, HALP, PNI and NRI scores were not associated with DR. Conclusion: Duration of diabetes, cardiometabolic control and GGT level are variables with predictive value for the prognosis of DR. No significant correlation was found between malnutrition-related inflammation markers and DR development and stage. © 2024, Pamukkale University. All rights reserved.
  • No Thumbnail Available
    Item
    Correction to: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study (Scientific Reports, (2024), 14, 1, (23556), 10.1038/s41598-024-75293-5)
    (Nature Research, 2025) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aşık E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Aydın E.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
    Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-75293-5, published online 09 October 2024 The original version of this Article contained an error in the spelling of the author Esra Aşık which was incorrectly given as Esra Aydın. The original Article has been corrected. © The Author(s) 2024.